Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL25236615 | 0.99 | CHRM2 (0.32) | HTTCHRM2CHRM4CHRM5CHRM1 | |
| Bromide SCHEMBL25201808 | 0.99 | HTT (0.31) | HTTCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL25525880 | 0.91 | ESR1 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL25208106 | 0.90 | ESR1 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL25233563 | 0.90 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25525863 | 0.88 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25525889 | 0.88 | CRHR1 (0.31) | — | |
| Bromide SCHEMBL25211054 | 0.87 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL25266851 | 0.87 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL25266852 | 0.87 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165978-A1 | Composition and A Method For Diagnosing And Treating Bacterial Infection | Hong Kong Centre for Cerebro-Cardiovascular Health Engineering Limited (HK) | 2023-06-01 | — | — | US | disclosed |
| US-20230165978-A1 | Composition and A Method For Diagnosing And Treating Bacterial Infection | Hong Kong Centre for Cerebro-Cardiovascular Health Engineering Limited (HK) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165978-A1 | Composition and A Method For Diagnosing And Treating Bacterial Infection | NOD2, PYCARD, NOD1 | HTT 3630/4885CHRM2 3603/4885CHRM4 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.